[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.173.45. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
December 2017

Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research

Author Affiliations
  • 1Department of Oncology, Pfizer, New York, New York
  • 2Department of Internal Medicine, UT Southwestern School of Medicine, Dallas, Texas
JAMA Oncol. 2017;3(12):1621-1622. doi:10.1001/jamaoncol.2017.1822

In the modern era of patient-centered drug development, the only way to translate biological and genomic discoveries into clinically meaningful therapies is through partnerships among academia, industry, and government. To ensure that the integrity of the research is beyond reproach, investigators who engage in such collaborations are expected to disclose relationships that could potentially have an influence on the results or interpretation of the research project.1,2 Herein, we examine several dimensions of conflicts of interest (COIs), describe the distinct entity of conflicting interests, and describe how they may affect clinical cancer research.

×